Accentuating the caveat emptor perspective with critical commentary on financial disclosure. I adopt a skeptical persona and look for chinks in the teflon coating of financial disclosure. My job is to identify financial warts. Perhaps a Black Swan. Disclosure: I do not hold positions in stocks mentioned for three trading days before or after blog post.
Sunday, June 11, 2006
Diabetes Spin
American Diabetes Association is having a major conference. That is why there is a veritable blizzard of press releases from various firms who are attempting to do work in this field. Most of the info is pathetic. You need FDA approval before anything goes live. Reporting pre trial data is quite frankly a pitch process for investors and VC money. The SEC should be attending not the FDA.